Published in World J Gastroenterol on September 21, 2009
Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection. World J Gastroenterol (2010) 1.01
Lipid metabolism and HCV infection. Viruses (2010) 0.96
Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care (2012) 0.91
Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol (2012) 0.90
Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne) (2015) 0.89
Insulin resistance and chronic liver disease. World J Hepatol (2011) 0.88
Association between metabolic syndrome and its individual components with viral hepatitis B. Am J Med Sci (2014) 0.83
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol (2014) 0.83
The interaction between HCV and nuclear receptor-mediated pathways. Pharmacol Ther (2011) 0.78
Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus. Hepat Res Treat (2016) 0.78
Association of hepatitis C virus with insulin resistance: evidences from animal studies and clinical studies. Hepat Mon (2012) 0.77
Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virol J (2011) 0.77
Efficacy of adding metformin to pegylated interferon and ribavirin in treatment naïve patients with chronic hepatitis C: a randomized double-blind controlled trial. Middle East J Dig Dis (2014) 0.76
Association of Overt Diabetes Mellitus with the Non-CC but not the CC Genotype of Interleukin-28B in Hepatitis C Virus Infected Patients. J Clin Transl Hepatol (2016) 0.75
Picolinic acid in patients with chronic hepatitis C infection: a preliminary report. Mediators Inflamm (2012) 0.75
Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus-Associated Type 2 Diabetes: A Mini Review. J Clin Transl Hepatol (2016) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol (1979) 27.52
IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science (2001) 11.56
Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell (2000) 5.92
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest (2002) 4.96
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med (2000) 4.83
Prevention of fat-induced insulin resistance by salicylate. J Clin Invest (2001) 4.74
Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 4.59
Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology (2002) 4.34
Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology (2004) 4.16
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology (1999) 4.14
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature (2008) 3.94
Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem (2002) 3.83
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (2001) 3.80
Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A (1998) 3.66
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology (2007) 3.61
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes (1998) 3.55
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology (2005) 3.47
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (2001) 2.90
Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord (2003) 2.89
Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol (2004) 2.81
The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) (2006) 2.71
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res (2006) 2.67
A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci U S A (2001) 2.61
Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol (1994) 2.58
Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A (2004) 2.54
Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology (2006) 2.49
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes (2007) 2.34
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol (2008) 2.28
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem (2005) 2.21
Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol (2007) 2.18
Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest (2005) 2.14
SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol (2004) 2.09
Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE (2005) 2.04
Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem (2000) 1.95
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology (2006) 1.92
Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology (2004) 1.91
Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut (2007) 1.91
Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89
Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology (2007) 1.85
Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care (2005) 1.83
Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol (2007) 1.75
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology (2003) 1.70
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol (2008) 1.69
Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol (2001) 1.68
Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol Metab (2006) 1.64
Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. Diabetes Care (2004) 1.55
PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest (2008) 1.55
The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology (2007) 1.50
Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin? J Hepatol (2009) 1.48
Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc (2000) 1.48
Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol (2007) 1.46
Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A (2007) 1.45
Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology (2007) 1.44
Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol (2005) 1.44
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab (2006) 1.34
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology (2005) 1.33
Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol (2003) 1.33
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol (2007) 1.23
Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol (2002) 1.21
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol (2007) 1.20
Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther (2006) 1.18
A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein. Biochim Biophys Acta (2005) 1.17
Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab (2003) 1.15
Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology (2008) 1.15
Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol (1999) 1.15
Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care (2006) 1.14
Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol (2006) 1.08
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology (2006) 1.08
Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol (2008) 1.06
p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. J Biol Chem (2007) 1.05
Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol (2008) 1.05
High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int (2007) 1.03
Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol (2003) 1.01
Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol (2006) 1.00
Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci (2002) 1.00
Correlation between insulin resistance and hepatitis C viral load. Hepatology (2006) 0.99
Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol (2007) 0.91
Insulin resistance and HCV: will new knowledge modify clinical management? J Hepatol (2006) 0.90
Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol (2009) 0.88
The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein. Biochimie (2006) 0.87
Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C. Hepatol Res (2007) 0.86
Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance. PPAR Res (2009) 0.83
Insulin resistance in chronic hepatitis B virus infection. Am J Gastroenterol (2009) 0.81
Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut (2006) 0.81
Hepatitis C virus and glucose and lipid metabolism. Diabetes Metab (2008) 0.79
Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answers. J Hepatol (2009) 0.79
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J (2006) 2.93
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology (2009) 2.66
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology (2002) 2.51
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol (2008) 2.39
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
Determination of interactions between tegument proteins of herpes simplex virus type 1. J Virol (2005) 2.31
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 2.24
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05
Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. Hepatology (2008) 2.03
Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2009) 2.02
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology (2009) 1.91
Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic (2008) 1.89
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol (2011) 1.88
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis (2007) 1.87
Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.79
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology (2014) 1.73
Transport and egress of herpes simplex virus in neurons. Rev Med Virol (2008) 1.72
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol (2009) 1.70
Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol (2008) 1.69
NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology (2005) 1.67
Subcutaneous emphysema in cavitary pulmonary tuberculosis without pneumothorax or pneumomediastinum. Lung India (2012) 1.67
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol (2008) 1.64
Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol (2007) 1.63
Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol (2009) 1.61
Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology (2013) 1.57
Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J (2006) 1.52
Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2012) 1.52
The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol (2011) 1.51
Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology (2009) 1.48
Islet-1 gene delivery improves myocardial performance after experimental infarction. Atherosclerosis (2012) 1.43
Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Med J Aust (2008) 1.42
Autoantibodies to oxidized low-density lipoprotein in patients with aortic regurgitation: association with aortic diameter size. Cardiology (2014) 1.41
Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. Heart Rhythm (2011) 1.41
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis (2002) 1.32
The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis (2006) 1.31
Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol (2004) 1.24
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology (2004) 1.24
HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology (2002) 1.23
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol (2007) 1.23
Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology (2010) 1.22
Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol (2002) 1.21
Thrombocytopenia due to rifampicin. Lung India (2012) 1.21
Pathogenesis of NASH: animal models. Clin Liver Dis (2007) 1.20
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med (2011) 1.19
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol (2010) 1.18
Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One (2011) 1.17
The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol (2005) 1.17
Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) (2002) 1.16
High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol (2013) 1.16
Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology (2008) 1.15
Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol (2002) 1.12
Circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart (2006) 1.11
Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation (2010) 1.11
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci (2006) 1.09
Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology (2009) 1.09
Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend (2007) 1.08
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology (2006) 1.08
The ribosome receptor, p180, interacts with kinesin heavy chain, KIF5B. Biochem Biophys Res Commun (2004) 1.08
The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol (2011) 1.07
A case of Goodpasture's syndrome complicating pregnancy with dialysis requiring renal failure responding to plasmapheresis and termination of pregnancy. Ren Fail (2013) 1.06
Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis (2012) 1.05
Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Mol Biol Cell (2003) 1.05
The heavy chain of conventional kinesin interacts with the SNARE proteins SNAP25 and SNAP23. Biochemistry (2002) 1.01
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2011) 1.01
Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum (2012) 1.00
Exercise and the liver: implications for therapy in fatty liver disorders. Semin Liver Dis (2012) 0.99
Recent findings on natural products with erectile-dysfunction activity. Phytochemistry (2003) 0.99
Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure. Heart (2007) 0.99
Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc Ther (2008) 0.99
Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett (2012) 0.99
Hepatitis C virus induces the cannabinoid receptor 1. PLoS One (2010) 0.98
Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int J Mol Med (2009) 0.98
Circulating apoptotic progenitor cells in patients with congestive heart failure. PLoS One (2008) 0.97
Mycoplasma hominis infection of a subdural haematoma in the peripartum period. Pathology (2003) 0.96
Lipid metabolism and HCV infection. Viruses (2010) 0.96
Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol (2004) 0.96
Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol (2005) 0.96
Treatment of post-catheterization femoral artery pseudo-aneurysm with para-aneurysmal saline injection. Am J Cardiol (2008) 0.95